All patients dosed with virus-based therapy for P. aeruginosa infections
All the cystic fibrosis (CF) patients participating in the Phase 2 portion of a clinical trial have been dosed with BX004, an inhaled virus-based therapy for chronic Pseudomonas aeruginosa bacterial infections of the lungs. Data from the first part of the Phase 1b/2a study (NCT05010577) showed the…